US Edition
Abivax SA (ABVX) Investor Outlook: Potential 19% Upside Amid Phase 3 Drug Trials
Summary by DirectorsTalk Interviews
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Abivax SA (ABVX) Investor Outlook: Potential 19% Upside Amid Phase 3 Drug Trials
Abivax SA (ABVX), a Paris-based biotechnology company, is making waves in the healthcare sector with its promising drug candidates targeting chronic inflammatory diseases. With a market capitalization of $4.43 billion and a current stock price of $69.76, Abivax is attracting investor attention, particularly for its potential upside of 19% as indicated by the average analyst target price of $83.02. Abivax’s lead drug candidate, obefazimod, is cur…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
